Biocon first to gain approval for generic of diabetes drug, liraglutide, in UK
India’s Biocon (BSE: 532523) says that it has received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its complex formulation liraglutide (6mg/ml solution for injection in pre-filled pen), which was filed through its European partner, Czech drugmaker Zentiva.
Liraglutide is the active ingredient of Danish firm Novo Nordisk’s (NOV: N) obesity drug Saxenda and is sold under the brand name Victoza for diabetes.
Biocon’s product is a drug-device combination formulation used in the treatment of type 2 diabetes mellitus, a disorder in which the body does not produce enough or respond normally to insulin, causing blood sugar (glucose) levels to be abnormally high.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze